Search Results

A total of 188 matching records were found.

ABTC1701
Pilot Surgical PK Study of Bemcentinib in Recurrent Glioblastoma Patients

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ABTC1801
Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations (ABTC-1801)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

BMTCTN1705
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 – Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

COM11114
A Multicenter Access and Distribution Protocol for unlicensed cryopreserved Cord Blood Units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

COM21115mp
Managed Access Program (MAP) Cohort Treatment Plan CAAA617A12001M to provide access to 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10020
10020 A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

ETCTN10061
A Phase 1 Study of MK-3475 (pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (NCI#10061)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10075
10075 A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia (ETCTN)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10129
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10170
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (ETCTN10170)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10204
10204: A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10218
10218: A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

ETCTN10222
ETCTN10222 A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10401
10401 A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J0656
A Phase I efficacy and safety study of HPV16-specific therapeutic DNA-Vaccinia vaccination in combination with topical imiquimod, in patients with HPV16 high grade cervical dysplasia (CIN2/3)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J09100
J09100- A safety and feasibility trial of boost vaccinations of a lethally irradiated, allogeneic pancreatic tumor cell vaccine transfected with the GM-CSF gene given alone or in combination with either a single intravenous dose or daily metronomic oral doses

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1055
Reduced intensity, partially HLA mismatched allogeneic BMT for hematologic malignancies using donors other than first-degree relatives

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J11143
Multiparametric MRI for assessing radiotherapy treatment response of prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J12106
A Phase II Trial of Reduced Intensity Conditioning of Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplant for High-risk Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1262
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J13105
Early Detection of Pancreatic Cystic Neoplasms

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1353
A Phase II Study of Epigenetic Therapy with Azacitidine and Entinostat with Concurrent Nivolumab in Subjects with Metastatic Non-Small Cell Lung Cancer.

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1366
Role of Human Papillomavirus in Head and Neck Squamous Cell Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1380
A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

J1394
Cancer of the Pancreas Screening-5 A multi-center clinical trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J14106
Non-invasive Detection of Cancer DNA in Blood and Urine

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1414
Neoadjuvant Immunotherapy in Resectable Non-Small-Cell Lung Cancer

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore

J14166
Prospective evaluation of high-dose (8 g/m2) systemic methotrexate in patients with breast cancer and leptomeningeal metastasis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1426
“A Randomized Phase II Study of Subventricular Zone (SVZ) Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme”

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J15168
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (r/r NHL) (ZUMA-4)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1553
J1553 - A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients with History of HPV16 Associated Cervical Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1557
Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-ß receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1560
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk localized and Locally Advanced Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1568
J1568: A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients with Surgically Resectable Adenocarcinoma of the Pancreas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1578
Sleep and Neurocognitive Function in Childhood Acute Lymphoid Leukemia Survivors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16118
A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16138
Phase I Safety Study of Stereotactic Radiosurgery with Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects with Recurrent or Metastatic Chordoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16146
J16146 - IMAGE II: Individualized Molecular Analyses Guide Efforts in Breast Cancer – Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J16163
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16173
J16173-Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, with or without Cyclophosphamide and GVAX Pancreas Vaccine in Patients with Metastatic Pancreatic Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1649
The Johns Hopkins NF1 biospecimen repository

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1708
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J17111
J17111 - A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma (C-145-04)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17118
J17118 - Prospective evaluation of determinants of resistance to endocrine therapy and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor in hormone receptor (HR) positive metastatic breast cancer (MBC)

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J17126
EUS-guided gastroenterostomy versus enteral stenting for palliation of malignant gastric outlet obstruction: a randomized clinical trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17127
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Protocol IT-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17128
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease [BMT CTN 1507]

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17130
Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17143
J17143 - A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17149
A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men with an Elevated PSA

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17181
A Pilot Study of Stereotactic Radiosurgical Hypophysectomy for Intractable Pain from Bone Metastases

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17187
Phase II Trial of Rucaparib in Patients with Metastatic and Non-Metastatic Hormone-Sensitive Prostate Cancer Harboring DNA Repair Gene Mutations (TRIUMPH)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17194
J17194 - A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1737
Preservation of Cognition and Neuropsychiatric Functioning with Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1801
A Pilot Study to evaluate the pharmacokinetic, pharmacodynamic, and resistance profile to RAF and MEK inhibitors in BRAF-V600E mutated recurrent gliomas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1804
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

J1807
J1807 - A Phase 1 Clinical Trial To Evaluate The Safety And Immunogenicity Of A Neoantigen DNA Vaccine Strategy In Pancreatic Cancer Patients Following Surgical Resection And Adjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1808
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors (ASTX029-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18100
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

Sites: Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

J18102
J18102 - Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibition

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18106
A Phase 1/1b multicenter study to evaluate the humanized anti-CD 73 antibody, CPI-006, as a single agent, or in combination with Ciforadenant with Pembrolizumab, and with Ciforadenant plus pembrolizumab in adult subjects with advanced cancers (CPI-006-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18114
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors (CA030-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18115
A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors (ASTX727)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18118
J18118 - The effect of CTLA4/PDL-1 Blockade following drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with intermediate stage of HCC using Durvalumab (MEDI4736) and Tremelimumab

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18144
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer (FLX475-02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18161
J18161-ADaptiVe Biomarker Trial that InformS Evolution of Therapy (ADVISE)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18163
J18163: A Phase I/II trial of combination immunotherapy with nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX following chemotherapy and radiotherapy for locally advanced pancreatic ductal adenocarcinomas (PDACs)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18166
Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID).

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1819
J1819 - Combination ATR and PARP Inhibitor (CAPRI) trial with AZD6738 and olaparib in recurrent ovarian cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1820
Communication Skills Training Initiatives for Cancer Patients and their Care Partners

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1825
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors (CA224-048)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1826
Studying the Pathologic and Immunologic Response after Ablative Radiation in Stage I Non-Small Cell Lung Cancer (SPARC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1836
J1836 - IMMUNe MOdulation in Early Stage Estrogen Receptor Positive Breast Cancer treated with NeoADjuvant Avelumab, Palbociclib, and endocrine Therapy: the ImmunoADAPT study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1840
Radiation Immunodynamics: The Immune Response to Standard Therapy in Patients with Glioblastoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1847
J1847: A phase I/II study of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in combination in metastatic pancreatic cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1850
Biomarker Detection in Men with Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1851
Randomized trial assessing induction of double strand breaks with androgen receptor partial agonist in patients on androgen suppression

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1866
J1866 - Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients with Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1878
J1878 - The Johns Hopkins Breast Cancer Program Initiative to Reduce the Discontinuation Rate of (Neo)adjuvant Endocrine Therapy through Symptom Monitoring and Management: A Feasibility Study

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J1885
Using 4R care sequences for lung cancer care: 4R is "Right Information and Right Care for the Right Patient at the Right time."

Sites: Johns Hopkins Bayview Medical Center

J19108
J19108 - A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19119
A Study of PET imaging of T-cell activation with [18F]F-AraG in advanced non-small cell lung cancer (NSCLC) patients undergoing PD-1/PD-L1-directed therapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19123
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (20190135)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19131
J19131- Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19136
A single arm phase II study to evaluate efficacy of T-DM1 with Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19140
J19140: A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19144
A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1924
A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR). NeoRay (Clinical Trial Protocol: CAAA603A12101)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1933
Nivolumab as a Non-Castrating Therapy for MMR-deficient and CDK12-Altered Prostate Cancer with PSA Recurrence After Local Therapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1940
J1940 - A Remote-Directed “Virtual” Clinical Trial in Metastatic Solid Tumors to Determine Feasibility of Evaluating Patient Response to Immunotherapy using Spliceosome Mutational Markers (PRISMM)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1956
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors (CA043-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1980
J1980 - A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1989
J1989 - A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1992
A Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) with non-escaped epitope targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1994
J1994: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined with Nivolumab and Ipilimumab for Patients with Resected MMR-p Colorectal and Pancreatic Cancer.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1999
A Phase II Single Arm Adaptive Weight Loss Study in Women with Early Stage Breast Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2007
J2007 - A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J20112
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant and Pre-malignant Peripheral Nerve Sheath Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J20113
J20113 - Biomarkers of response and immune-related adverse events (irAEs) with immune checkpoint inhibitor (ICI) therapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J20119
“Real-time Augmented Reality Coaching for the Breath-Hold technique for Pancreatic SBRT patients”

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J20120
A Phase I/II, First-In-Human, Multi-Part, OpenLabel, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications (DF1001-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J20121
J20121: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients with Potentially Resectable Hepatocellular Carcinoma (HCC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J20124
J20124 - A Phase Ib, Open-Label, Multicenter Study To Evaluate The Safety, Pharmacokinetics, And Activity Of Belvarafenib As A Single Agent And In Combination With Either Cobimetinib Or Cobimetinib Plus Atezolizumab In Patients With Nras-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2020
A Phase II trial for the use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the treatment of BCG naïve Non-muscle invasive Urothelial Carcinoma of the Bladder

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2043
J2043 - Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J2044
J2044 - PASS-01- Pancreatic Adenocarcinoma Signature Stratification for treatment – 01

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J2046
J2046 - EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (J2J-MC-JZLA)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2047
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination with Docetaxel for the Treatment of Advanced Prostate Cancer with Elevated DKK1

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2048
IMPROVE: Improving Cancer Care by Incorporating the Patient’s Voice into On-treatment Symptom Management

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Suburban Hospital, Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

J2053
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J2066
"Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer"

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2075
J2075 - An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2076
Phase 1 and phase 2a, first-in-human study of DRP-104, a glutamine antagonist, in adult patients with advanced solid tumors (DRA-104-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2077
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J2078
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in second line or CUE-101 Combination Therapy with Pembrolizumab in first line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2085
Neoadjuvant Targeting of Myeloid Cell Populations in Combination with Nivolumab in Head & Neck Cancer Patients Undergoing Surgery

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2089
A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (LOXO-IDH-20002)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2096
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging Patients with Non-Small-Cell Lung Cancer (NSCLC) who are Eligible for Treatment with Anti-PD-1 Monotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2097
A Phase I First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvalumab (MEDI4736) in Participants With Advanced Solid Tumours (D9950C00001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2108
J2108 - A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2111
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2112
J2112: Multi-agent low dose chemotherapy (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan) followed by maintenance olaparib and pembrolizumab in untreated metastatic pancreatic ductal adenocarcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2121
J2121 - A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK 1308A (Coformulated MK 1308/MK 3475) in Combination with Lenvatinib (E7080/MK 7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2126
A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors (SY-5609-101)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2127
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination with BMS-986207 (antiTIGIT antibody) and Nivolumab in Subjects with Advanced Solid Tumors (CPG-03-101)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2128
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM) (Sponsor Protocol Number: DCL-16-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2139
A Phase 2 Study to Evaluate the Efficacy and Safety of belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET) (015-00)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2161
Pro-GRID - A Phase I Study of Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2170
A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC) [EV-104]

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

N1202
Phase I Study of AZD1775 (adavosertib) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

N1403
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA011202
A011202 A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNA011801
A011801, The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNA021502
A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNA0577
N0577 CODEL: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNA071401
A071401 Phase II Trial of SMO/AKT/NF2CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations/CDK Pathway Mutations

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA071601
A071601 Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA091902
A091902 A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNA151216
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

NCTNCOV2006
(NCICOVID) NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study. COVID-19 RELATED SUBMISSION

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNE4512
E4512 A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

NCTNEA1181
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNEA4151
EA4151 A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEA4181
EA4181 A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients equal to 70 years old with Untreated Mantle Cell Lymphoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNEA5163
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center

NCTNEA6174
EA6174 STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNEA8183
EA8183 A Phase III Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEA8192
EA8192 A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNEAQ172
EAQ172: Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEAY131-A
EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEAY131-C2
EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEAY131-E
EAY131-E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEAY131-L
EAY131-L Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations (NCI-MATCH sub-protocol)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEAY131-Z1E
EAY131-Z1E LOXO-101 in Patients with Tumors with NTRK Fusions (NCI-MATCH sub-protocol)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEAY131-Z1G
EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEAZ171
EAZ171 Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNGY012
GY012 A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNGY018
GY018 A Phase III Randomized, Placebo-controlled Study of Pembrolizumab (MK-3475, NSC#776864) in Addition to Paclitaxel and Carboplatin for measurable stage III or IVA, Stage IVB or recurrent endometrial cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNGY019
GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNGY022
NRG-GY022: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNMDS
NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Natural History Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNN1216
R1216 Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Suburban Hospital

NCTNNCC003
CC003 Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center

NCTNNCC008
NRG-CC008, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNPPEPN1924
PEPN1924: A PHASE 2 STUDY OF DS-8201A (NSC# 807708, IND# 153036) IN ADOLESCENTS, OR YOUNG ADULTS WITH RECURRENT HER2+ OSTEOSARCOMA

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNS1609
S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNS1806
S1806 Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

PAALL1621
AALL1621 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PACCL0922
A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PACNS0831
ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PACNS1123
ACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PAHOD04B1
Hodgkin Disease (HD) Banking Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PANHL1131
ANHL1131, Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PAPEC1621I
APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PAREN03B2
AREN03B2 Renal Tumors Classification, Biology, and Banking Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PASCT1221
A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PrE0506
DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

SIB2091
Niraparib Plus Carboplatin in Patients with Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Sites: Sibley Memorial Hospital

SIB2092
BrafPanc: A Phase II Trial of Binimetinib in combination with Encorafenib in patients with Pancreatic Malignancies and a somatic BRAFV600E Mutation

Sites: Sibley Memorial Hospital

SIB2093
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

Sites: Sibley Memorial Hospital

SIB2094
Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung02)

Sites: Sibley Memorial Hospital

SIB2106
A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR Mutant cfDNA in Plasma After Initiation of Osimertinib

Sites: Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

SIB2117
A Phase 1B/2, Open-Label, Randomized Platform Study Evaluating The Efficacy And Safety Of AB928-Based Treatment Combinations In Patients With Metastatic Colorectal Cancer

Sites: Sibley Memorial Hospital

SIBJ2095
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) (CX-839-014).

Sites: Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

SIBNCTNS2001
S2001-Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

Sites: Sibley Memorial Hospital

SIBZ2132
Impact of the COVID-19 Pandemic on Willingness to Participate in Breast Cancer Clinical Trials

Sites: Sibley Memorial Hospital

TBCRC022
A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

TBCRC034
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed Intraductal Papilloma without Atypia or Flat Epithelial Atypia (FEA) by Core Needle Biopsy (TBCRC 034)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital